Silo Pharma, Inc. (SILO): Entry into a Material Definitive Agreement
Silo Pharma, Inc. (SILO) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On October 13, 2026, Silo Pharma, Inc. (the “Company”) entered into an asset purchase agreement (the “Agreement”) with Larry King (the “Seller”). Pursuant to the Agreement, the Seller agreed to sell, and the Company agreed to
How this was made
The 30-second read
Why it matters
The transaction represents a primary corporate action that could affect share price due to dilution and lock‑up constraints.
Market read
Primary disclosure of a material definitive agreement; likely short‑term price impact for SILO.
What to watch
Details of the software's strategic value and any earn‑out provisions are not disclosed.
Background
SEC Form 8‑K filed by Silo Pharma on Oct 14, 2026, announcing a purchase agreement and issuance of shares to the seller.
Ticker impact
Silo Pharma filed an 8‑K reporting an asset purchase agreement and issuance of 150,000 shares to the seller, constituting a material definitive agreement and unregistered equity sale.
downward pressure as the market prices in dilution and lock‑up restrictions
New equity issuance is a primary corporate action; dilution and lock‑up typically depress share price in the short term.
Market effects
Limited to biotech/pharma sector; may signal increased M&A activity but impact is company‑specific.
No broader regional effect.
Minimal global relevance.
Counterpoint
If the acquired software accelerates pipeline development, the dilution could be offset by future revenue growth.
Key entities
- companySilo Pharma, Inc.
Biopharma company issuing shares for software assets.
- individualLarry King
Seller of the software and recipient of the issued shares.
